Ulcerative Colitis | Unmet Need | Moderate to Severe | US/EU | 2025
TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine ’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), a JAK inhibitor (Pfizer’s Xeljanz), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s Stelara) are the mainstays of treatment for moderate to severe ulcerative colitis (UC). However, these agents have safety risks and efficacy limitations. Newer alternatives, such as a JAK inhibitor (AbbVie’s Rinvoq), IL-23 inhibitors (Eli Lilly’s Omvoh, AbbVie’s Skyrizi, and Johnson & Johnson Innovative Medicine’s Tremfya), and S1P-R modulators (BMS’s Zeposia and Pfizer’s Velsipity) have expanded the treatment options, but significant unmet need remains for patients whose UC is refractory to these therapies. Emerging agents with novel mechanisms of action—including anti-TL1A therapies and next-generation small molecules—offer potential breakthroughs, but their long-term efficacy, safety, and positioning within the treatment paradigm remains to be seen.
Questions answered
- What are the treatment drivers and goals in moderate to severe UC?
- How do current therapies perform on treatment drivers and goals for moderate to severe UC?
- In addition to efficacy, which drug attributes most strongly influence physician prescribing behaviors, and which have a limited impact?
- What are the prevailing areas of unmet need and hidden opportunity in the treatment of moderate to severe UC?
- What trade-offs across clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new UC drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 32 European gastroenterologists, fielded in December 2024
Key companies: AbbVie, Johnson & Johnson Innovative Medicine, Pfizer, Takeda, Eli Lilly, BMS
Key drugs: Humira and biosimilars, Remicade and biosimilars, Entyvio, Stelara, Omvoh, Skyrizi, Tremfya, Rinvoq, Zeposia, Velsipity
Product description
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Key feature
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
